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Where Are We Now?
A
s populations increase in size,
and as total hip arthroplasty is
increasingly performed in
younger patients, the burden on
healthcare systems grows. Implant
survivorship beyond two decades is
becoming an imperative. Unfortu-
nately, many hip implants have been
introduced—often as minor modifica-
tions of a successful design—only to fail
catastrophically. Joint registries pio-
neered by the Scandinavian countries are
powerful tools with which to compare
implants in the long-term, but detection
of underperforming implants sooner
remains difficult because registries gen-
erally have focused on the endpoint of
revision, rather than on signs of failure
that may be evident earlier on. By the time
it is apparent that an implant does not
have acceptable long-term survival,
many thousands, if not tens of thousands,
have been implanted.
Radiostereometric Analysis (RSA)
has been shown to be adept at detect-
ing implants that are prone to early
failure long before the evidence was
apparent from longitudinal studies or
registry data [2]. However, RSA can be
time consuming and labor intensive, and
it calls for modified implants. For these
reasons, RSA has not become established
in many centers around the world. Tra-
ditionally, most studies came from those
centers (mainly in Europe) where it has
long been an integral part of the research
program of institutions that have focused
on it. This situation has recently changed
with the advent of greater computing
power and software that accelerates the
process, and model-based systems eradi-
cating the need for modified components.
But, as with the continuing iteration of hip
components potentially leading to a failed
design, the modification of RSA must not
diminish its accuracy in the quest for it to
be easier and quicker.
Where Do We Need To Go?
A consensus is required on how new
implants, or new designs of existing
implants, are introduced in to clinical
use. In the UK, the National Institute
for Health and Care Excellence, in
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response to the widespread use of
poorly performing implants, recom-
mended that surgeons only implant
total hip replacements that had solid
long-term data, with a minimum sur-
vival of 95% at 10 years [3]. This
approach, while focusing fully on
patient safety, stifles innovation and
development. There needs to be a
system by which new implants can be
evaluated and introduced in a carefully
regulated and controlled manner. The
call for RSA to evaluate all new
implants is not a new idea [4]. But to
properly investigate effective evalua-
tion of new implants, there needs to be
harmony between the orthopaedic
community and the implant manufac-
turers, with investigations involving
research tools such as RSA and good-
quality clinical outcome data.
This system should also incorporate
laboratory-based testing, and limited
clinical release in groups with careful
early- and long-term followup to con-
tinue in the original cohort. The
authors of the current study should be
commended for their examination of a
new prosthesis. The study is a worthy
example of how to: (1) Properly
investigate a novel prosthesis, (2)
confirm that the results of a clinical
RSA trial of the same implant are
useful, and (3) provide strong guidance
on likely long-term outcome regarding
fixation. The strength of this paper is
based on its adherence to the
consensus guidelines for the use of
RSA in orthopaedics [6]. Further
papers of this type can only improve
our understanding of how implants
fail, and help identify those implants
that have a long-term future.
How Do We Get There?
While the current study should be
commended, there are still some
potential concerns. The system is
expensive and arduous for the implant
companies and it does not encourage
engagement by orthopaedic surgeons
unless they are attached to large
research centers with the infrastructure
to perform the necessary investigation.
The Beyond Compliance system
was developed in the UK in response
to the NICE guidelines [1]. The system
is voluntary on the part of the implant
manufacturers, but after the device has
been registered and the preclinical
testing results have been submitted, the
device is released clinically, in a con-
trolled manner. The patients undergo
in-depth postmarketing surveillance.
This enables any surgeon to register as
a Beyond Compliance surgeon and use
implants that are newly arrived to the
market, obtaining specific consent
from each patient for additional fol-
lowup data to be obtained. The results
of this surveillance then directly feeds
in to the Orthopaedic Data Evaluation
Panel (ODEP), the implant then gains
a rating and becomes available for
general use [5]. The ODEP rating
system has already been adopted in
several countries around the world,
probably due to its simplicity, but also
because of its rigorous nature.
Hopefully, by developing and
maintaining a structured, cost-effec-
tive, and accessible method of device
evaluation, we can avoid repeating the
mistakes of the past.
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